Back to search
Steroid-Refractory Acute Graft-Versus-Host Disease
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Steroid-Refractory Acute Graft-Versus-Host Disease trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Steroid-Refractory Acute Graft-Versus-Host Disease trials you may qualify forThis study is a prospective, multicenter, open-label, phase II clinical trial designed to evaluate the safety and efficacy of moxibustion in patients with stero…
This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients w…
A study to evaluate the safety and preliminary efficacy of iMSC in subjects with SR-aGVHD
The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroi…
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing,…
This is a prospective, multicenter, randomized controlled trial designed to evaluate whether the combination of ruxolitinib and etanercept provides superior eff…
This study is a randomized, double-blind, placebo-controlled, multicenter Phase III trial to compare the efficacy and safety of remestemcel-L-rknd (remestemcel-…
The purpose of this trial is the comparative evaluation of overall response rate (ORR) in paediatric participants with steroid-refractory acute graft-versus-hos…